- Email: [email protected]
THE CHINA ACUTE MYOCARDIAL INFARCTION REGISTRY: A NATIONAL REGISTRY-QUALITY IMPROVEMENT INTEGRATED PROGRAM IN CHINA
A174 JACC April 1, 2014 Volume 63, Issue 12
Acute Coronary Syndromes The China Acute Myocardial Infarction Registry: A National Registry-Quality Improvement Integrated Program in China Poster Contributions Hall C Sunday, March 30, 2014, 9:45 a.m.-10:30 a.m.
Session Title: Acute Coronary Syndromes: STEMI Abstract Category: 1. Acute Coronary Syndromes: Clinical Presentation Number: 1190-260 Authors: Haiyan Xu, YueJin Yang, Jingang Yang, Wei Li, Eric Peterson, Matthew Roe, Ying Xian, Marc Sabatine, Stephen Wiviott, Fuwai Hospital, Beijing, People’s Republic of China, Brigham and Women’s Hospital, DCRI, USA Background: Acute myocardial infarction (AMI) is now a major cause of emergency medical care, hospitalization and mortality in China. However there are limited information on how clinical characteristics, care quality and outcome vary among Chinese patients and hospitals. We launched the China AMI (CAMI) registry, as a national registry to obtain real-world information on AMI epidemiology, treatment, outcome and cost. Methods: The CAMI registry was designed as a prospective, multicenter, observational registry with an integrated research and education platform for AMI care. Eligible patients must be admitted within 7 days of acute ischemic symptoms with a primary diagnosis of AMI [ST elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)]. Clinical data, laboratory and imaging results, treatments, outcomes and cost are to be collected. Follow-up visits are planned through 2 years. Results: The registry was launched in January 2013. At the time of this abstract submission, 102 different-level hospitals (including province level, district level, and county level representing typical Chinese governmental models) from 27 provinces and 4 large cities (municipalities directly under central government) throughout mainland of China are participating in the registry. Through September 2013, 8,185 patients with AMI (71.4% STEMI patients, 25.1% NSTEMI patients and 3.5% patients uncertain) have been enrolled. 74.9% of patients were male. The median age was 63 years (2299 years). 52% of patients had hypertension and 20% had diabetes. 46.3% of patients were current smokers. 95.2% of patients received aspirin, 94.5% received clopidogrel and 97.2% received a statin. The in-hospital mortality rate was 5.3% for STEMI and 4.2% for NSTEMI. At the Scientific Sessions the authors will present further data on early results. Conclusions: The CAMI registry represents a novel unified, national AMI registry-research-education platform for surveillance, multicenter clinical research, and quality improvement for AMI care in China, a geographically large and economically diverse country that is the most populous in the world. These represent the first results from CAMI.
Acute Coronary Syndromes The China Acute Myocardial Infarction Registry: A National Registry-Quality Improvement Integrated Program in China Poster Contributions Hall C Sunday, March 30, 2014, 9:45 a.m.-10:30 a.m.
Session Title: Acute Coronary Syndromes: STEMI Abstract Category: 1. Acute Coronary Syndromes: Clinical Presentation Number: 1190-260 Authors: Haiyan Xu, YueJin Yang, Jingang Yang, Wei Li, Eric Peterson, Matthew Roe, Ying Xian, Marc Sabatine, Stephen Wiviott, Fuwai Hospital, Beijing, People’s Republic of China, Brigham and Women’s Hospital, DCRI, USA Background: Acute myocardial infarction (AMI) is now a major cause of emergency medical care, hospitalization and mortality in China. However there are limited information on how clinical characteristics, care quality and outcome vary among Chinese patients and hospitals. We launched the China AMI (CAMI) registry, as a national registry to obtain real-world information on AMI epidemiology, treatment, outcome and cost. Methods: The CAMI registry was designed as a prospective, multicenter, observational registry with an integrated research and education platform for AMI care. Eligible patients must be admitted within 7 days of acute ischemic symptoms with a primary diagnosis of AMI [ST elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)]. Clinical data, laboratory and imaging results, treatments, outcomes and cost are to be collected. Follow-up visits are planned through 2 years. Results: The registry was launched in January 2013. At the time of this abstract submission, 102 different-level hospitals (including province level, district level, and county level representing typical Chinese governmental models) from 27 provinces and 4 large cities (municipalities directly under central government) throughout mainland of China are participating in the registry. Through September 2013, 8,185 patients with AMI (71.4% STEMI patients, 25.1% NSTEMI patients and 3.5% patients uncertain) have been enrolled. 74.9% of patients were male. The median age was 63 years (2299 years). 52% of patients had hypertension and 20% had diabetes. 46.3% of patients were current smokers. 95.2% of patients received aspirin, 94.5% received clopidogrel and 97.2% received a statin. The in-hospital mortality rate was 5.3% for STEMI and 4.2% for NSTEMI. At the Scientific Sessions the authors will present further data on early results. Conclusions: The CAMI registry represents a novel unified, national AMI registry-research-education platform for surveillance, multicenter clinical research, and quality improvement for AMI care in China, a geographically large and economically diverse country that is the most populous in the world. These represent the first results from CAMI.